



Commonwealth of Massachusetts
Executive Office of Health and Human Services
Office of Medicaid
www.mass.gov/masshealth

MassHealth
All Provider Bulletin 336 (Corrected)
December 2021

TO: All Providers Participating in MassHealth

FROM: Amanda Cassel Kraft, Assistant Secretary for MassHealth

RE: Coverage of and Payment for the Administration of (1) Tixagevimab Co-Packaged with Cilgavimab, and (2) Remdesivir in an Outpatient Setting

Background

On December 8, 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for Tixagevimab co-packaged with Cilgavimab for the pre-exposure prophylaxis of COVID-19. Through this bulletin, MassHealth will cover this service consistent with the EUA. In addition, through this bulletin, and based on current medical evidence, MassHealth will cover Remdesivir administered to MassHealth members on an outpatient basis by MassHealth-enrolled acute outpatient hospitals, community health centers, and physicians, as further described below.

This bulletin applies to members enrolled in MassHealth fee-for-service, the Primary Care Clinician (PCC) plan, or a primary care accountable care organization (ACO). Information about coverage through MassHealth managed care entities (MCEs) and the Program of All-inclusive Care for the Elderly (PACE) will be included in a forthcoming MCE bulletin.

Coverage of and Payment for the Administration of Tixagevimab Co-Packaged with Cilgavimab for the Pre-Exposure Prophylaxis of COVID-19

MassHealth will cover the administration of Tixagevimab co-packaged with Cilgavimab by providers enrolled in the MassHealth acute outpatient hospital, community health center, and physician programs for pre-exposure prophylaxis of COVID-19 only when the injections are administered in a manner fully compliant with the FDA's EUA. For additional information, please see the FDA's [EUA](#) and its accompanying [Fact Sheet for Healthcare Providers](#).

Effective for dates of service on or after December 8, 2021, providers enrolled in the MassHealth acute outpatient hospital, community health center, and physician programs may bill and receive payment for the EUA-compliant administration of Tixagevimab co-packaged with Cilgavimab, as described in the table below. MassHealth will issue transmittal letters that formally add these codes to the relevant provider manuals. The Executive Office and Health and Human Services (EOHHS) will formally establish these rates, which are consistent with Medicare, through administrative bulletins or amendments to 101 CMR 446.00: *COVID-19 Payment Rates for Certain Community Health Care Providers*.

**MassHealth
All Provider Bulletin 336 (Corrected)
December 2021
Page 2 of 3**

Code	Rate	Description	Effective for Dates of Service On or After
Q0220 SL	\$0.00	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	12/8/2021
M0220	\$150.50	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	12/8/2021
M0221	\$250.50	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	12/8/2021

MassHealth
All Provider Bulletin 336 (Corrected)
December 2021
Page 3 of 3

Coverage of and Payment for the Administration of Remdesivir in an Outpatient Setting

In 2020, the FDA issued an EUA for the inpatient administration of Remdesivir to certain adults and pediatric patients for the treatment of COVID-19 requiring hospitalization. Subsequent medical evidence now supports the administration of Remdesivir to certain individuals in an outpatient setting as a treatment for COVID-19. Accordingly, pursuant to 130 CMR 406.413(C), and effective for dates of service on or after December 22, 2021, MassHealth will reimburse MassHealth-enrolled acute outpatient hospitals, community health centers, and physicians for the administration of Remdesivir in an outpatient setting in accordance with this bulletin. Any such provider must administer Remdesivir only to members who are 12 years of age or older, weigh more than 40 kilograms, have mild-to-moderate COVID-19, are at risk of progression to severe disease, and have experienced symptoms for seven days or fewer.

Providers administering Remdesivir pursuant to this bulletin should bill MassHealth using HCPCS code J3490. MassHealth will pay MassHealth-enrolled acute outpatient hospitals administering Remdesivir pursuant to this bulletin in accordance with the Rate Year 2022 Acute Hospital Request for Applications and Contract, as amended. MassHealth will pay MassHealth-enrolled physicians and community health centers administering Remdesivir pursuant to this bulletin in accordance with 101 CMR 317.00: *Rates for Medicine Services*.

MassHealth Website

This bulletin is available on the [MassHealth Provider Bulletins](#) web page.

[Sign up](#) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

Questions

Dental Services

Phone: (800) 207-5019; TTY: (800) 466-7566

Long-Term Services and Supports

Phone: (844) 368-5184 (toll free)
Email: support@masshealthtss.com
Portal: www.MassHealthLTSS.com
Mail: MassHealth LTSS, PO Box 159108, Boston, MA 02215
Fax: (888) 832-3006

All Other Provider Types

Phone: (800) 841-2900; TTY: (800) 497-4648
Email: providersupport@mahealth.net
Fax: (617) 988-8974